CollPlant Biotechnologies’ (CLGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Monday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

A number of other equities analysts have also weighed in on CLGN. Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Thursday, August 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $11.50.

CollPlant Biotechnologies Stock Down 4.6%

Shares of CLGN opened at $2.26 on Monday. The business’s 50 day moving average price is $2.54 and its 200-day moving average price is $2.23. CollPlant Biotechnologies has a 52 week low of $1.31 and a 52 week high of $4.98. The stock has a market cap of $28.75 million, a P/E ratio of -2.00 and a beta of 1.57.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, August 20th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.57). CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%.The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $8.91 million. On average, equities analysts anticipate that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Investors Weigh In On CollPlant Biotechnologies

A number of hedge funds have recently added to or reduced their stakes in the stock. AMH Equity Ltd raised its stake in CollPlant Biotechnologies by 28.7% during the 2nd quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock valued at $219,000 after buying an additional 35,849 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in CollPlant Biotechnologies by 3.7% during the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock valued at $690,000 after buying an additional 18,000 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC raised its stake in CollPlant Biotechnologies by 13.0% during the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock valued at $744,000 after buying an additional 63,000 shares during the last quarter. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.